{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T17:44:08Z","timestamp":1768153448013,"version":"3.49.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T00:00:00Z","timestamp":1585785600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"AryoGen Pharmed Company","award":["105,431"],"award-info":[{"award-number":["105,431"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.clinthera.2020.03.009","type":"journal-article","created":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T07:43:17Z","timestamp":1587541397000},"page":"848-859","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Efficacy and Safety of Proposed Bevacizumab Biosimilar BE1040V in Patients With Metastatic Colorectal Cancer: A Phase III, Randomized, Double-blind, Noninferiority Clinical Trial"],"prefix":"10.1016","volume":"42","author":[{"given":"Hamid","family":"Rezvani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyed Mohammadreza","family":"Mortazavizadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abolghasem","family":"Allahyari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amirabbas","family":"Nekuee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Safa Najjar","family":"Najafi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammadreza","family":"Vahidfar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7831-5403","authenticated-orcid":false,"given":"Mojtaba","family":"Ghadyani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adnan","family":"Khosravi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siroos","family":"Qarib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alireza","family":"Sadeghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohsen","family":"Esfandbod","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohsen","family":"Rajaeinejad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alireza","family":"Rezvani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Hajiqolami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehrdad","family":"Payandeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Babak","family":"Shazad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nassim","family":"Anjidani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0061-171X","authenticated-orcid":false,"given":"Shahab","family":"Meskinimood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Afsaneh","family":"Alikhasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moein","family":"Karbalaeian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sina","family":"Salari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2020.03.009_bib1","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/j.1529-8019.2007.00144.x","article-title":"Skin lightening preparations and the hydroquinone controversy","volume":"20","author":"Draelos","year":"2007","journal-title":"Dermatol Ther"},{"issue":"12 Suppl","key":"10.1016\/j.clinthera.2020.03.009_bib2","doi-asserted-by":"crossref","first-page":"4187","DOI":"10.1002\/1097-0142(19930615)71:12+<4187::AID-CNCR2820711805>3.0.CO;2-T","article-title":"Colon and rectum cancer. Patterns of spread and implications for workup","volume":"71","author":"Niederhuber","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2020.03.009_bib3","doi-asserted-by":"crossref","first-page":"29765","DOI":"10.1038\/srep29765","article-title":"Patterns of metastasis in colon and rectal cancer","volume":"6","author":"Riihim\u00e4ki","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.clinthera.2020.03.009_bib4","series-title":"Andrews' Diseases of the Skin","first-page":"1","author":"James","year":"2011"},{"key":"10.1016\/j.clinthera.2020.03.009_bib5","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1055\/s-0029-1242463","article-title":"Surgical management of colorectal lung metastasis","volume":"22","author":"Villeneuve","year":"2009","journal-title":"Clin Colon Rectal Surg"},{"key":"10.1016\/j.clinthera.2020.03.009_bib6","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jcmgh.2017.01.006","article-title":"Colorectal cancer liver metastasis: evolving paradigms and future directions","volume":"3","author":"Zarour","year":"2017","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1016\/j.clinthera.2020.03.009_bib7","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clinthera.2020.03.009_bib8","first-page":"67","article-title":"Colorectal cancer initial diagnosis: screening colonoscopy, diagnostic colonoscopy, or emergent surgery, and tumor stage and size at initial presentation","volume":"15","author":"Moreno","year":"2016","journal-title":"Clin Colorectal Cancer"},{"issue":"suppl_3","key":"10.1016\/j.clinthera.2020.03.009_bib9","doi-asserted-by":"crossref","first-page":"iii1","DOI":"10.1093\/annonc\/mdu260","article-title":"Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"25","author":"Van Cutsem","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2020.03.009_bib10","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1159\/000315730","article-title":"Metastatic colorectal cancer: from improved survival to potential cure","volume":"78","author":"Gallagher","year":"2010","journal-title":"Oncology"},{"key":"10.1016\/j.clinthera.2020.03.009_bib11","first-page":"862","article-title":"Colorectal cancer prognosis twenty years later","volume":"16","author":"Bujanda","year":"2010","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.clinthera.2020.03.009_bib12","doi-asserted-by":"crossref","first-page":"15065","DOI":"10.1038\/nrdp.2015.65","article-title":"Colorectal cancer","volume":"1","author":"Kuipers","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.clinthera.2020.03.009_bib13","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/S1470-2045(10)70232-1","article-title":"Biomarkers to predict the clinical efficacy of bevacizumab in cancer","volume":"11","author":"Jubb","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clinthera.2020.03.009_bib14","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.sder.2009.04.001","article-title":"Management of hyperpigmentation in darker racial ethnic groups","volume":"28","author":"Grimes","year":"2009","journal-title":"Semin Cutan Med Surg"},{"key":"10.1016\/j.clinthera.2020.03.009_bib15","series-title":"Guideline on Similar Biological Medicinal Products Containing Monoclonal Antibodies\u2014Non-Clinical and Clinical Issues","year":"2012"},{"key":"10.1016\/j.clinthera.2020.03.009_bib16","series-title":"International Generic and Biosimilar Medicines Association","year":"2020"},{"key":"10.1016\/j.clinthera.2020.03.009_bib17","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1177\/1076029614522545","article-title":"A\u00a0comparison between recombinant activated factor VII (Aryoseven) and Novoseven in patients with congenital factor VII deficiency","volume":"21","author":"Faranoush","year":"2014","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.clinthera.2020.03.009_bib18","first-page":"84","article-title":"A\u00a0double-blind, randomized comparison study between Zytux vs MabThera in treatment of CLL with FCR regimen: non-inferiority clinical trial","volume":"12","author":"Toogeh","year":"2018","journal-title":"Int J Hematol Oncol Stem Cell Res"},{"key":"10.1016\/j.clinthera.2020.03.009_bib19","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/annonc\/mdn730","article-title":"Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study","volume":"20","author":"Bidard","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2020.03.009_bib20","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1038\/sj.bjc.6603095","article-title":"A\u00a0phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients","volume":"94","author":"Mabro","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clinthera.2020.03.009_bib21","series-title":"Clinical Practice Guidelines in Oncology","author":"National Comprehensive Cancer Network","year":"2020"},{"key":"10.1016\/j.clinthera.2020.03.009_bib23","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2020.03.009_bib24","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/S1470-2045(14)70330-4","article-title":"FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial","volume":"15","author":"Heinemann","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clinthera.2020.03.009_bib25","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1093\/annonc\/mdv130","article-title":"Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: final results for first-line treatment from the ITACa randomized clinical trial","volume":"26","author":"Amadori","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2020.03.009_bib26","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.2007.14.9930","article-title":"Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized Phase III study","volume":"26","author":"Saltz","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clinthera.2020.03.009_bib27","doi-asserted-by":"crossref","first-page":"682","DOI":"10.5732\/cjc.011.10188","article-title":"Efficacy and tolerability of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial","volume":"30","author":"Guan","year":"2011","journal-title":"Chin J Cancer"},{"key":"10.1016\/j.clinthera.2020.03.009_bib28","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1186\/1471-2407-13-611","article-title":"Bifractionated CPT-11 with LV5FU2 infusion (FOLFIRI-3) in combination with bevacizumab: clinical outcomes in first-line metastatic colorectal cancers according to plasma angiopoietin-2 levels","volume":"13","author":"Kim","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clinthera.2020.03.009_bib29","doi-asserted-by":"crossref","first-page":"535","DOI":"10.4103\/ijc.IJC_394_17","article-title":"Comparative pharmacokinetics, efficacy, and tolerability of bevacizumab biosimilar to reference bevacizumab in patients with metastatic colorectal cancer","volume":"54","author":"Apsangikar","year":"2017","journal-title":"Indian J Cancer"},{"key":"10.1016\/j.clinthera.2020.03.009_bib30","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(12)70477-1","article-title":"Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial","volume":"14","author":"Bennouna","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clinthera.2020.03.009_bib31","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1159\/000320520","article-title":"Treatment of colorectal cancer with and without bevacizumab: a Phase III study","volume":"78","author":"Stathopoulos","year":"2010","journal-title":"Oncology"},{"key":"10.1016\/j.clinthera.2020.03.009_bib32","series-title":"Avastin Bevacizumab Injection, Solution","year":"2019"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291820301739?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291820301739?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:52:20Z","timestamp":1758963140000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291820301739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S0149291820301739"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2020.03.009","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Proposed Bevacizumab Biosimilar BE1040V in Patients With Metastatic Colorectal Cancer: A Phase III, Randomized, Double-blind, Noninferiority Clinical Trial","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2020.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}